Pfizer Analysis
Industry Group 4: Manufacturing
Edgar Santos
Sean Moore
Matthew Karambatos
AGENDA
■ Company Snapshot – Pfizer Inc.
■ Investment Thesis – What is driving our optimism?
■ SWOT Analysis
■ Valuation – Financial Statements and Model Outputs
■ Investment Recommendation – Buy, Sell, or Hold?
COMPANY SNAPSHOT
PFIZER’S HISTORY
Founded in 1849 by cousins Charles Pfizer and
Charles Earnhart in Brooklyn New York
In 1944 Pfizer became the world leader in
manufacturing Penicillin which at the time was
considered one of the world's top medical
breakthroughs.
1997 - Fortune magazine names Pfizer the world's
most admired pharmaceuticals company.
Since the millenium Pfizer has embarked in many
mergers, with companies such as Warner Lambert
in 2000, UpJohn in 2002, and Wyeth in 2009. The
result is a giant pharma company with over
100,000 employees worldwide.
In 2018 GlaxoSmithKline and Pfizer merged their
consumer healthcare divisions into a single entity
which would have annual sales of around $12.7
billion.
COMPANY SNAPSHOT
BUSINESS UNITS OF PFIZER INC.
INNOVATIVE MEDICINES ESTABLISHED MEDICINES CONSUMER HEALTHCARE
Biosimilar medication: Vaccine: Prevnar 13 Anticoagulant: Eliquis - used
Enbrel - used for various protects from infection such as a blood thinner for blood
types of arthritis as pneumonia and meningitis. clots and strokes.
Gene Therapy : Oncology: Ibrance - Small molecule: Viagra - used
PF - 06939926 - used to treat advanced to treat erectile dysfunction.
an early stage therapy metastatic breast cancer.
designed to target Duchenne Small Molecule:
Muscular Dystrophy. Anti-Epliptic: Lyrica - Chantrix - aids individuals
it can be used to treat attempting to quit smoking
Rare Disease - Elelyso - fibromyalgia, diabetic
provides patients with a peripheral neuropathy, and
Gaucher disease treatment pain associated with spinal
option. injuries.
COMPANY SNAPSHOT
MANAGEMENT &
CORPORATE GOVERNANCE
CEO - Albert Bourla CFO - Frank D’Amelio CSO - Mikael Dolsten
Also serves as Pfizer’s Chairman. Responsible for corporate finance, Focuses on advancing scientific
audit, treasury, operations leadership in small molecules,
25 year career previously COO planning and analysis. biotherapeutics, gene therapies,
overseeing commercial strategy. and vaccines.
Frank has helped in numerous Mikael is a named contributor on
PhD in Biotechnology of mergers and acquisitions several patents and has published
Reproduction. mentioned earlier. roughly 150 articles in medical
journals.
COMPANY SNAPSHOT
MARKET HIGHLIGHTS
Market Capitalization $210.88 Billion
Price to Earnings 14.02
Ratio
Dividend Yield 4.01%
Earnings per Share $2.36
Last dividend paid per 0.38
share
Total number of 5.534 billion
outstanding shares
COMPARABLES ANALYSIS
COMPANY SNAPSHOT
REVENUE DRIVERS BY
BUSINESS UNIT
INNOVATIVE MEDICINES ESTABLISHED MEDICINES CONSUMER HEALTHCARE
Biosimilar medication: Vaccine: Prevnar 13 Anticoagulant: Eliquis -
Enbrel: $5.95B in sales in 2019, up 2019 revenues up $1.38B
Over 23 million people living 2.6% from 2018, as it is the from 2018, at $7.71B, up 22%
worldwide with Arthritis, and best preventative for from the year before
growing pneumonia
Small molecule: Viagra -
Gene Therapy :
Oncology: Ibrance - $500M in sales in 2019,
PF - 06939926 -
Sales of $1.28B in 2019 vs down from 2018 due to
Affects 1 in 3500 live male
births, drug placed on fast-track $1.13B in 2018 patent expiry in 2012
by FDA as there is no other drug
that has been able to treat DMD Anti-Depression: Zoloft- Small Molecule: Chantix -
Sales of $78M in 2019 vs Sold $1.11B in 2019, up 7%
Rare Disease - Genotropin - $75M in 2018 from 2018
Sales stayed flat at $142 million
in 2019 from 2018
INVESTMENT THESIS
1. VACCINE TECHNOLOGY
SARS-CoV-2 Vaccine:
Prevnar 13 Sales, 2011-2018
Otherwise known as BNT162b2, it is a
messenger RNA (mRNA) vaccine developed in
conjunction with Germany’s BioNTech for the $6B
prevention of COVID-19 disease. 2018
Total
Prevnar 13 Pneumonia Vaccine:
International
A vaccine part of the long-standing Prevnar $4B
vaccine family, a staple in the Western World
for prevention of Pneumonia in children ages 6
weeks to 17 years.
$2B
mRNA Platform Progress: US
A vastly new vaccine technology platform that
allows vaccine makers to skip the usage of live
or attenuated virus vaccines, that have long
proven an issue for immunocompromised Source: Axios
individuals.
INVESTMENT THESIS
BNT162b2 VACCINE
Currently undergoing Phase 2/3 Trials in various countries including; the United States, Argentina, Brazil, Germany, South
Africa and Turkey. A total of 43,998 participants will be enrolled in the trial. Double-Blinded, Randomized, 1:1.
In an earlier Phase 1 clinical trial on humans, BNT162b2 produced a surprisingly strong immune response in all 45
participants, with average neutralizing antibody concentrations being 2.8x those of naturally infected patients who had
been hospitalized.
Source: Pfizer
INVESTMENT THESIS
BNT162b2 VACCINE
The agreement with BioNTech is of capped
financial value, with BioNTech receiving an
upfront payment of $185M USD, an equity
investment of $113M USD (asset) and further Source: Various incl. NYT
consideration topping out at $563M USD, for
total maximum consideration of $748M USD.
Pfizer is required to fund 100% of
development costs initially, with 50% of those
costs being repaid to Pfizer by BioNTech upon
commercialization of the BNT162b2 vaccine.
Global supply will be produced at sites in;
Belgium, Germany, and the US. 100M doses
available in 2020, 1.3B by the end of 2021.
Source: Pfizer
INVESTMENT THESIS
BNT162b2 VACCINE
Below is a graphic outlining the prevalence of systemic Below is a graphic outlining the mean density of at least
reactions in the Phase 1/2 trials of BNT162b1 and b2, 50% neutralizing antibodies per microliter of blood, with
directly from Pfizer’s peer-reviewed release. the HCS bar comparing it to post-infection human
convalescent serum.
Source: Pfizer Source: Pfizer
INVESTMENT THESIS
PREVNAR 13 VACCINE
Prevnar 13 has consistently been a top-seller
for Pfizer, especially so after a 2014 decision
by the CDC to also recommend its use in adults
65 and older. Below: A chart outlining the coverage rates of PCV3 vaccines across
different WHO regions, outlining the large growth prospects for Prevnar 13
One of the most significant effects of lower in South-East Asia, and the Eastern Mediterranean. There is also significant
income countries rising into the ranks of the growth possible in the African region.
middle income nations is the effect on public
health protocols, and by default vaccinations.
Patent only expires in 2026.
In provinces across Canada, Prevnar 13 is a
recommended vaccine with 3 doses given in
the first year of a child’s life, as well as a
recommended vaccine for those 50 years or
over in the province who are at risk of Invasive
Pneumococcal Disease. The incidence of this
disease has been steadily increasing in the
province since 2003, to 9.4 per 100,000
people in 2012.
Source: WHO
INVESTMENT THESIS
mRNA VACCINE
PLATFORM
One aspect of the current race for a COVID-19
vaccine that cannot be underscored is the
rapid development of messenger RNA (mRNA)
vaccines being seen.
Pfizer’s BNT162b2 may be the first mRNA
vaccine ever approved for use in humans,
closely followed by Moderna’s mRNA-1273.
Regulatory clout in regards to this approval, as
well as a continued and expanded partnership
with BioNTech, will allow Pfizer to transfer
knowledge gained during the development of
BNT162b2 into other mRNA vaccines.
The Global mRNA Vaccine/Therapeutic market
will double to just over $2.2B in revenue by
2026, will likely faster growth in years beyond. Source: VisionGain
INVESTMENT THESIS
2. ESTABLISHED MEDICINES FINDING
NEW/EXPANDED USES
Ibrance (CDK 4/6 Inhibitor):
Ibrance is currently used as a Breast
Cancer treatment, providing a major
benefit over commonly used
chemotherapy by being significantly
easier on the patient.
Eliquis (Anti-coagulant):
Eliquis is one of the most commonly
used anticoagulants in the world, with
an extension on specific patents
keeping it under the sole distribution of
Pfizer until 2026.
INVESTMENT THESIS
IBRANCE/AROMASIN
Ibrance is currently used in conjunction with a
hormonal breast cancer treatment involving
aromatase inhibitors (AIs). This treatment is
primarily used in post-menepausal women and
men, primarily of an elevated age.
Ibrance is used in an alternate treatment to
chemotherapy, one that causes significantly less
severe and pronounced symptoms than
chemotherapy, allowing Ibrance and co-operative
AIs to capture market share from chemotherapy
through a dampened effect on quality of life.
Roughly 30% of women who develop early stage
breast cancer go on to develop metastatic cancer,
making Ibrance and AIs a go-to treatment option.
Alongside Ibrance, Pfizer also sells an AI of their
own. Pfizer received approval from the EU in 2005
for Aromasin to be used in women with early stage
breast cancer, allowing for distribution of a solely
Pfizer produced treatment.
INVESTMENT THESIS
IBRANCE/AROMASIN
The market for Ibrance and Aromasin may
increase as Western nations age, with the US
population of ages greater than 65 jumping
from 15% in 2016 to 21% in 2030, or an
absolute jump from 49.2M to 73.1M citizens
over the age of 65.
With Breast Cancer being the most prevalent
form of cancer in men and women, calculations
produced with estimates from the NIH
produce an increase in market size for Breast
Cancer patients over 60 years of age is
30.30% by 2030 and 52.76% by 2050. Source: CDC
If Ibrance continues to capture the same
market share of cancer treatments, product
revenue would jump by the corresponding
amounts in market size. This is a best estimate
scenario.
Ibrance sales expected to jump to $9.218B by
2024, from $4.118B in 2018.
Source: US Census/CDC
INVESTMENT THESIS
ELIQUIS ANTICOAGULANT
Eliquis is one of the world’s top selling
anticoagulants, created in a partnership with
Bristol-Myers Squibb that sees revenue on the
drug shared between the two companies.
The patent on Eliquis is protected until 2026,
allowing for another 6 years of avoidance of
competition from generics.
Currently, Eliquis carries with it an 11% CAGR,
with the entirety of the prescription drugs
industry holding a CAGR of 6.9% up until 2024.
Unconsidered in these growth rates for Eliquis,
and namely the anticoagulant sub-sector, is
the advancing prevalence of endothelial and
circulatory complications caused by infections,
highlighted by the COVID-19 Pandemic.
Source: EvaluatePharma
INVESTMENT THESIS
3. MANAGEMENT
EXPERTISE/REPUTATIONAL
ENHANCEMENT
Since the appearance of the SARS-CoV-2 Virus
in East Asia in December 2019, Pfizer made a
commitment to producing therapeutics and
vaccines that would help lift the world out of the
current pandemic. Pfizer has successfully
completed the quickest ever turnaround for a
vaccine in regards to a novel virus.
Pfizer’s management team has long been
heralded as a market leader, and their Source: WSJ
qualifications are more than enough to back it up.
50% of the individuals of Pfizer’s exec leadership
team hold a degree in Sciences, with 25% of
them holding a PH.D in their respective field.
When compared to CEO compensation for other
major players in the Pharma industry, Pfizer
CEOs earned less in compensation per Billion
dollars in company earnings for 2019 than all but
Sanofi’s CEO.
SWOT ANALYSIS
STRENGTHS & WEAKNESSES
Strengths: Weaknesses:
Pfizer is predicted to continue topping the Net Income and free cash flow have been on the decline
prescription drugs market, with revenues over the course of the 2018-2020. This is due in part to
coming in at a projected $51.2B in 2024, at patents expiring in 2017 and become generic drugs.
a 2018-2024 CAGR of roughly 16.3%.
Pfizer carries a significant amount of debt. $50 billion in
Pfizer is the 2nd largest pharmaceutical long term debt is on the books as of 2020’s June
company in the world based on revenue. Quarterly report.
Healthy pipeline of 6 treatments in phase 2-
3 of clinical trials. within various indications. Large acquisitions that Pfizer has recently performed
hasn’t resulted in steller return on equity as proof of the
Spends aggressively on R&D and has declining net income over the last few years.
resulted in numerous blockbuster products
such as Advil, Viagra, Chapstick, Robitussin, Pfizer faces competition in the dominance of Prevnar
and many drugs specialized toward specific vaccines, especially from Merck whose own
indications. Pneumococcal vaccine in development covers 15 strains
vs Pfizer’s 13.
SWOT ANALYSIS
OPPORTUNITIES & THREATS
Opportunities: Threats:
Currently, Pfizer holds the largest market As research on non-pharmaceutical interventions grows,
share of any company in the prescription the ability of physicians to knock off drug treatment by
drugs sector, an industry expected to grow introducing early measures and early screening of disease
at a CAGR of 6.9% up to 2024, and may dampen growth.
extensively beyond.
A continued FDA push to bring more low-cost generics to
Global sales at-risk from patent expiration market may also dampen growth in the industry, although
will drop to a 10-year low across the it remains to be seen how well the FDA or companies that
industry in 2020 and 2021, allowing Pfizer produce generics can break the patents held by big
to bolster its cash position for future R&D Pharma companies.
as gene therapy and mRNA therapeutics
demand greater research.
PRESCRIPTION DRUG SECTOR
RANKINGS 2024
VALUATION
KEY INPUTS & ASSUMPTIONS
VALUATION
KEY INPUTS & ASSUMPTIONS
VALUATION
OUTPUTS & EXPECTATIONS
Base Year 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 Terminal Year
Revenue Growth Rate 1.46% 1.46% 1.46% 1.46% 1.46% 1.36% 1.26% 1.15% 1.05% 0.95% 0.95%
Revenues $ 49,704.00 $ 50,428.79 $ 51,164.15 $ 51,910.23 $ 52,667.19 $ 53,435.20 $ 54,160.30 $ 54,840.40 $ 55,473.53 $ 56,057.80 $ 56,591.47 $ 57,130.22
EBITDA (Operating Margin) 71.05% 68.94% 66.84% 64.73% 62.63% 60.52% 58.42% 56.31% 54.21% 52.10% 50.00% 50.00%
EBITDA (Operating Income) $ 35,314.00 $ 35,054.30 $ 34,475.60 $ 33,872.88 $ 33,245.56 $ 32,593.06 $ 32,655.02 $ 32,716.98 $ 32,778.94 $ 32,840.90 $ 32,902.86 $ 28,565.11
Tax Rate 12.67% 12.67% 12.67% 12.67% 12.67% 12.67% 15.74% 18.80% 21.87% 24.93% 28.00% 28.00%
EBIT(1-T) $ 30,840.05 $ 30,613.26 $ 30,107.87 $ 29,581.51 $ 29,033.67 $ 28,463.83 $ 27,516.68 $ 26,565.72 $ 25,610.97 $ 24,652.41 $ 23,690.06 $ 20,566.88
- Reinvestment $ 23,362.40 $ 5,783.95 $ 2,984.33 $ 3,027.85 $ 3,072.00 $ 3,600.21 $ 4,128.41 $ 4,656.61 $ 5,184.82 $ 5,713.02 $ 5,713.02
FCFF $ 7,250.86 $ 24,323.92 $ 26,597.18 $ 26,005.82 $ 25,391.83 $ 23,916.47 $ 22,437.31 $ 20,954.35 $ 19,467.59 $ 17,977.04 $ 14,853.86
NOL $ - $ - $ - $ - $ - $ - $ - $ - $ - $ - $ - $ -
Cost of Capital 5.66% 5.66% 5.66% 5.66% 5.66% 5.62% 5.58% 5.53% 5.49% 5.45% 5.45%
Cumulated Discount Factor 0.9465 0.8958 0.8478 0.8024 0.7594 0.7191 0.6811 0.6454 0.6118 0.5801
PV (FCFF) $6,862.58 $21,788.64 $22,549.17 $20,867.18 $19,283.49 $17,197.14 $15,281.53 $13,523.11 $11,909.41 $10,428.97
Terminal Cash Flow $ 14,853.86
Terminal Cost of Capital 5.45%
Terminal Value $ 330,085.70
PV (Terminal Value) $ 191,491.65
PV (CFs over next 10 years) $159,691.22
Sum of PV $ 351,182.87
Probability of Failure 10%
Proceeds if Firm fails $27,814.00
Value of Operating Assets $ 318,845.98
- Debt $ 123,119.50
- Minority Interests $0.00
+ Cash $ 22,794.00
+ Non-operating Assets $0.00
Value of Equity $ 218,520.48
- Value of Options $0.00
Value of Equity in Common Stocks $ 218,520.48
Number of Shares 5534
Estimated Value/Share $ 39.49
Price $ 36.85
Price as % of Value 93.32%
INVESTMENT REC.
OUTPUTS & EXPECTATIONS
CANADIAN ANALYSTS US ANALYSTS OUR RECOMMENDATION
RBC Capital (Buy) - Price Morgan Stanley (Hold) - Strong buy, as we have
Target of $43.00 Price Target of $42.00 valued Pfizer at $48.68
Cantor Fitzgerald (Buy) - SVB Leerink (Buy) - per share, a 32%
Price Target of $53.00 Price Target of $42.00 increase compared to
Credit Suisse Group Cowen & Co. (Buy) - the stock's current price
(Buy) - Price Target of Price Target of $48.00 of $36.85
$41.30 Citigroup (Hold) -Price
Target of $37.00
